AimVion’s anti-inflammatory peptide technology is the outcome of years of research in the genetics of autoimmunity, particularly in the interplay between Human Endogenous Retroviruses (HERVs) and autoimmunity. Our proprietary technology is based on the fact that a group of HERVs have been adapted by the human immune system in an anti-inflammatory role. A particular member of this HERV group, unique to humans and very close primate relatives, helps to control the autoimmune reactions in some patients (Rheumatology and Arthritis, in press).
Through analyzing the molecular mechanism of how this HERV helps reduce symptoms of autoimmunity, AimVion has developed a proprietary technology for designing extremely potent anti-inflammatory peptides with a mechanism of action unlike any other currently used drugs.
The anti-inflammatory peptides are, small and simple in design and easily produced in large quantities and very effective anti-inflammation agents.
Our lead compound is capable of reducing the arthritis score in the collagen induced arthritis (CIA) mouse model by a staggering 99% in doses that will translate to between 0.1 and 1mg in humans.
AimVion focuses on bringing its lead against Rheumatoid Arthrtitis to clinical validation and development of its portfolio of anti-inflammatory peptides in general.